nodes	percent_of_prediction	percent_of_DWPC	metapath
Capecitabine—Nucleic Acid Synthesis Inhibitors—Cytarabine—lymphatic system cancer	0.656	1	CiPCiCtD
Capecitabine—CDA—Cytarabine—lymphatic system cancer	0.236	0.86	CbGbCtD
Capecitabine—TYMS—Methotrexate—lymphatic system cancer	0.0302	0.11	CbGbCtD
Capecitabine—CYP2C9—Teniposide—lymphatic system cancer	0.00819	0.0299	CbGbCtD
Capecitabine—TYMS—Podofilox—Teniposide—lymphatic system cancer	0.000528	0.4	CbGdCrCtD
Capecitabine—TYMS—Vinorelbine—Vincristine—lymphatic system cancer	0.000314	0.238	CbGdCrCtD
Capecitabine—TYMS—Vinblastine—Vincristine—lymphatic system cancer	0.000216	0.164	CbGdCrCtD
Capecitabine—TYMS—Azacitidine—Fludarabine—lymphatic system cancer	0.000134	0.102	CbGdCrCtD
Capecitabine—TYMS—Azacitidine—Cytarabine—lymphatic system cancer	0.000127	0.096	CbGdCrCtD
Capecitabine—Vision blurred—Carmustine—lymphatic system cancer	5e-05	0.000728	CcSEcCtD
Capecitabine—Hypersensitivity—Fludarabine—lymphatic system cancer	4.98e-05	0.000726	CcSEcCtD
Capecitabine—Tremor—Carmustine—lymphatic system cancer	4.97e-05	0.000724	CcSEcCtD
Capecitabine—Oedema—Bleomycin—lymphatic system cancer	4.96e-05	0.000723	CcSEcCtD
Capecitabine—Erythema—Mitoxantrone—lymphatic system cancer	4.93e-05	0.000718	CcSEcCtD
Capecitabine—Infection—Bleomycin—lymphatic system cancer	4.93e-05	0.000718	CcSEcCtD
Capecitabine—Anaemia—Carmustine—lymphatic system cancer	4.9e-05	0.000714	CcSEcCtD
Capecitabine—Back pain—Vincristine—lymphatic system cancer	4.9e-05	0.000714	CcSEcCtD
Capecitabine—Vomiting—Teniposide—lymphatic system cancer	4.89e-05	0.000713	CcSEcCtD
Capecitabine—Sepsis—Methotrexate—lymphatic system cancer	4.88e-05	0.000711	CcSEcCtD
Capecitabine—Thrombocytopenia—Bleomycin—lymphatic system cancer	4.86e-05	0.000707	CcSEcCtD
Capecitabine—Asthenia—Fludarabine—lymphatic system cancer	4.85e-05	0.000707	CcSEcCtD
Capecitabine—Rash—Teniposide—lymphatic system cancer	4.85e-05	0.000707	CcSEcCtD
Capecitabine—Dermatitis—Teniposide—lymphatic system cancer	4.85e-05	0.000706	CcSEcCtD
Capecitabine—Dysgeusia—Mitoxantrone—lymphatic system cancer	4.83e-05	0.000704	CcSEcCtD
Capecitabine—Headache—Teniposide—lymphatic system cancer	4.82e-05	0.000702	CcSEcCtD
Capecitabine—Pruritus—Fludarabine—lymphatic system cancer	4.79e-05	0.000697	CcSEcCtD
Capecitabine—Back pain—Mitoxantrone—lymphatic system cancer	4.77e-05	0.000695	CcSEcCtD
Capecitabine—Leukopenia—Carmustine—lymphatic system cancer	4.75e-05	0.000692	CcSEcCtD
Capecitabine—Anorexia—Bleomycin—lymphatic system cancer	4.73e-05	0.000689	CcSEcCtD
Capecitabine—Thrombophlebitis—Methotrexate—lymphatic system cancer	4.71e-05	0.000687	CcSEcCtD
Capecitabine—Diabetes mellitus—Methotrexate—lymphatic system cancer	4.69e-05	0.000683	CcSEcCtD
Capecitabine—Anaemia—Vincristine—lymphatic system cancer	4.68e-05	0.000682	CcSEcCtD
Capecitabine—Vision blurred—Mitoxantrone—lymphatic system cancer	4.65e-05	0.000677	CcSEcCtD
Capecitabine—Photosensitivity—Methotrexate—lymphatic system cancer	4.65e-05	0.000677	CcSEcCtD
Capecitabine—Polyuria—Methotrexate—lymphatic system cancer	4.65e-05	0.000677	CcSEcCtD
Capecitabine—Hypotension—Bleomycin—lymphatic system cancer	4.63e-05	0.000675	CcSEcCtD
Capecitabine—Diarrhoea—Fludarabine—lymphatic system cancer	4.63e-05	0.000674	CcSEcCtD
Capecitabine—Hypertension—Carmustine—lymphatic system cancer	4.58e-05	0.000667	CcSEcCtD
Capecitabine—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	4.57e-05	0.000667	CcSEcCtD
Capecitabine—Nausea—Teniposide—lymphatic system cancer	4.57e-05	0.000666	CcSEcCtD
Capecitabine—Anaemia—Mitoxantrone—lymphatic system cancer	4.56e-05	0.000664	CcSEcCtD
Capecitabine—Vertigo—Vincristine—lymphatic system cancer	4.55e-05	0.000663	CcSEcCtD
Capecitabine—Hepatic failure—Methotrexate—lymphatic system cancer	4.54e-05	0.000661	CcSEcCtD
Capecitabine—Leukopenia—Vincristine—lymphatic system cancer	4.53e-05	0.00066	CcSEcCtD
Capecitabine—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	4.52e-05	0.000658	CcSEcCtD
Capecitabine—Chest pain—Carmustine—lymphatic system cancer	4.52e-05	0.000658	CcSEcCtD
Capecitabine—Myalgia—Carmustine—lymphatic system cancer	4.52e-05	0.000658	CcSEcCtD
Capecitabine—Anxiety—Carmustine—lymphatic system cancer	4.5e-05	0.000656	CcSEcCtD
Capecitabine—Paraesthesia—Bleomycin—lymphatic system cancer	4.45e-05	0.000649	CcSEcCtD
Capecitabine—Malaise—Mitoxantrone—lymphatic system cancer	4.45e-05	0.000648	CcSEcCtD
Capecitabine—Dyspnoea—Bleomycin—lymphatic system cancer	4.42e-05	0.000644	CcSEcCtD
Capecitabine—Renal failure acute—Methotrexate—lymphatic system cancer	4.42e-05	0.000644	CcSEcCtD
Capecitabine—Leukopenia—Mitoxantrone—lymphatic system cancer	4.41e-05	0.000643	CcSEcCtD
Capecitabine—Hypertension—Vincristine—lymphatic system cancer	4.37e-05	0.000637	CcSEcCtD
Capecitabine—Confusional state—Carmustine—lymphatic system cancer	4.36e-05	0.000636	CcSEcCtD
Capecitabine—Oedema—Carmustine—lymphatic system cancer	4.33e-05	0.000631	CcSEcCtD
Capecitabine—Dermatitis exfoliative—Methotrexate—lymphatic system cancer	4.32e-05	0.00063	CcSEcCtD
Capecitabine—Decreased appetite—Bleomycin—lymphatic system cancer	4.31e-05	0.000628	CcSEcCtD
Capecitabine—Myalgia—Vincristine—lymphatic system cancer	4.31e-05	0.000628	CcSEcCtD
Capecitabine—Cough—Mitoxantrone—lymphatic system cancer	4.3e-05	0.000627	CcSEcCtD
Capecitabine—Infection—Carmustine—lymphatic system cancer	4.3e-05	0.000627	CcSEcCtD
Capecitabine—Vomiting—Fludarabine—lymphatic system cancer	4.3e-05	0.000627	CcSEcCtD
Capecitabine—Rash—Fludarabine—lymphatic system cancer	4.26e-05	0.000621	CcSEcCtD
Capecitabine—Dermatitis—Fludarabine—lymphatic system cancer	4.26e-05	0.000621	CcSEcCtD
Capecitabine—Hypertension—Mitoxantrone—lymphatic system cancer	4.26e-05	0.00062	CcSEcCtD
Capecitabine—Pain—Bleomycin—lymphatic system cancer	4.24e-05	0.000618	CcSEcCtD
Capecitabine—Thrombocytopenia—Carmustine—lymphatic system cancer	4.24e-05	0.000618	CcSEcCtD
Capecitabine—Headache—Fludarabine—lymphatic system cancer	4.24e-05	0.000617	CcSEcCtD
Capecitabine—Tachycardia—Carmustine—lymphatic system cancer	4.22e-05	0.000616	CcSEcCtD
Capecitabine—Chest pain—Mitoxantrone—lymphatic system cancer	4.2e-05	0.000612	CcSEcCtD
Capecitabine—Myalgia—Mitoxantrone—lymphatic system cancer	4.2e-05	0.000612	CcSEcCtD
Capecitabine—Arthralgia—Mitoxantrone—lymphatic system cancer	4.2e-05	0.000612	CcSEcCtD
Capecitabine—Anxiety—Mitoxantrone—lymphatic system cancer	4.18e-05	0.00061	CcSEcCtD
Capecitabine—Cerebrovascular accident—Methotrexate—lymphatic system cancer	4.16e-05	0.000607	CcSEcCtD
Capecitabine—Lethargy—Methotrexate—lymphatic system cancer	4.16e-05	0.000607	CcSEcCtD
Capecitabine—Discomfort—Mitoxantrone—lymphatic system cancer	4.15e-05	0.000604	CcSEcCtD
Capecitabine—Oedema—Vincristine—lymphatic system cancer	4.13e-05	0.000602	CcSEcCtD
Capecitabine—Anorexia—Carmustine—lymphatic system cancer	4.13e-05	0.000601	CcSEcCtD
Capecitabine—Infection—Vincristine—lymphatic system cancer	4.11e-05	0.000598	CcSEcCtD
Capecitabine—Feeling abnormal—Bleomycin—lymphatic system cancer	4.09e-05	0.000595	CcSEcCtD
Capecitabine—Osteoarthritis—Methotrexate—lymphatic system cancer	4.08e-05	0.000594	CcSEcCtD
Capecitabine—Confusional state—Mitoxantrone—lymphatic system cancer	4.06e-05	0.000591	CcSEcCtD
Capecitabine—Nervous system disorder—Vincristine—lymphatic system cancer	4.05e-05	0.00059	CcSEcCtD
Capecitabine—Thrombocytopenia—Vincristine—lymphatic system cancer	4.05e-05	0.000589	CcSEcCtD
Capecitabine—Hypotension—Carmustine—lymphatic system cancer	4.04e-05	0.000589	CcSEcCtD
Capecitabine—Oedema—Mitoxantrone—lymphatic system cancer	4.02e-05	0.000586	CcSEcCtD
Capecitabine—Nausea—Fludarabine—lymphatic system cancer	4.02e-05	0.000585	CcSEcCtD
Capecitabine—Infection—Mitoxantrone—lymphatic system cancer	4e-05	0.000583	CcSEcCtD
Capecitabine—Hyperhidrosis—Vincristine—lymphatic system cancer	3.99e-05	0.000582	CcSEcCtD
Capecitabine—Shock—Mitoxantrone—lymphatic system cancer	3.96e-05	0.000577	CcSEcCtD
Capecitabine—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	3.94e-05	0.000575	CcSEcCtD
Capecitabine—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	3.94e-05	0.000574	CcSEcCtD
Capecitabine—Urticaria—Bleomycin—lymphatic system cancer	3.94e-05	0.000574	CcSEcCtD
Capecitabine—Anorexia—Vincristine—lymphatic system cancer	3.94e-05	0.000574	CcSEcCtD
Capecitabine—Tachycardia—Mitoxantrone—lymphatic system cancer	3.93e-05	0.000572	CcSEcCtD
Capecitabine—Body temperature increased—Bleomycin—lymphatic system cancer	3.92e-05	0.000571	CcSEcCtD
Capecitabine—Insomnia—Carmustine—lymphatic system cancer	3.92e-05	0.00057	CcSEcCtD
Capecitabine—Skin disorder—Mitoxantrone—lymphatic system cancer	3.91e-05	0.00057	CcSEcCtD
Capecitabine—Irritability—Methotrexate—lymphatic system cancer	3.89e-05	0.000567	CcSEcCtD
Capecitabine—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	3.89e-05	0.000567	CcSEcCtD
Capecitabine—Paraesthesia—Carmustine—lymphatic system cancer	3.89e-05	0.000566	CcSEcCtD
Capecitabine—Mood swings—Methotrexate—lymphatic system cancer	3.86e-05	0.000563	CcSEcCtD
Capecitabine—Hypotension—Vincristine—lymphatic system cancer	3.86e-05	0.000563	CcSEcCtD
Capecitabine—Dyspnoea—Carmustine—lymphatic system cancer	3.86e-05	0.000562	CcSEcCtD
Capecitabine—Anorexia—Mitoxantrone—lymphatic system cancer	3.84e-05	0.000559	CcSEcCtD
Capecitabine—Ataxia—Methotrexate—lymphatic system cancer	3.84e-05	0.000559	CcSEcCtD
Capecitabine—Liver function test abnormal—Methotrexate—lymphatic system cancer	3.77e-05	0.000549	CcSEcCtD
Capecitabine—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	3.76e-05	0.000549	CcSEcCtD
Capecitabine—Decreased appetite—Carmustine—lymphatic system cancer	3.76e-05	0.000548	CcSEcCtD
Capecitabine—Hypotension—Mitoxantrone—lymphatic system cancer	3.76e-05	0.000548	CcSEcCtD
Capecitabine—Insomnia—Vincristine—lymphatic system cancer	3.74e-05	0.000545	CcSEcCtD
Capecitabine—Gastrointestinal disorder—Carmustine—lymphatic system cancer	3.74e-05	0.000545	CcSEcCtD
Capecitabine—Paraesthesia—Vincristine—lymphatic system cancer	3.71e-05	0.000541	CcSEcCtD
Capecitabine—Pain—Carmustine—lymphatic system cancer	3.7e-05	0.000539	CcSEcCtD
Capecitabine—Constipation—Carmustine—lymphatic system cancer	3.7e-05	0.000539	CcSEcCtD
Capecitabine—Breast disorder—Methotrexate—lymphatic system cancer	3.69e-05	0.000537	CcSEcCtD
Capecitabine—Toxic epidermal necrolysis—Methotrexate—lymphatic system cancer	3.67e-05	0.000535	CcSEcCtD
Capecitabine—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	3.67e-05	0.000534	CcSEcCtD
Capecitabine—Hypersensitivity—Bleomycin—lymphatic system cancer	3.65e-05	0.000532	CcSEcCtD
Capecitabine—Paraesthesia—Mitoxantrone—lymphatic system cancer	3.61e-05	0.000527	CcSEcCtD
Capecitabine—Decreased appetite—Vincristine—lymphatic system cancer	3.59e-05	0.000523	CcSEcCtD
Capecitabine—Dyspnoea—Mitoxantrone—lymphatic system cancer	3.59e-05	0.000523	CcSEcCtD
Capecitabine—Gastrointestinal disorder—Vincristine—lymphatic system cancer	3.57e-05	0.00052	CcSEcCtD
Capecitabine—Feeling abnormal—Carmustine—lymphatic system cancer	3.57e-05	0.00052	CcSEcCtD
Capecitabine—Fatigue—Vincristine—lymphatic system cancer	3.56e-05	0.000519	CcSEcCtD
Capecitabine—Asthenia—Bleomycin—lymphatic system cancer	3.56e-05	0.000518	CcSEcCtD
Capecitabine—Dyspepsia—Mitoxantrone—lymphatic system cancer	3.54e-05	0.000516	CcSEcCtD
Capecitabine—Gastrointestinal pain—Carmustine—lymphatic system cancer	3.54e-05	0.000516	CcSEcCtD
Capecitabine—Constipation—Vincristine—lymphatic system cancer	3.53e-05	0.000515	CcSEcCtD
Capecitabine—Pain—Vincristine—lymphatic system cancer	3.53e-05	0.000515	CcSEcCtD
Capecitabine—Asthma—Methotrexate—lymphatic system cancer	3.53e-05	0.000514	CcSEcCtD
Capecitabine—Pruritus—Bleomycin—lymphatic system cancer	3.51e-05	0.000511	CcSEcCtD
Capecitabine—Decreased appetite—Mitoxantrone—lymphatic system cancer	3.5e-05	0.00051	CcSEcCtD
Capecitabine—Fatigue—Mitoxantrone—lymphatic system cancer	3.47e-05	0.000506	CcSEcCtD
Capecitabine—Pain—Mitoxantrone—lymphatic system cancer	3.44e-05	0.000501	CcSEcCtD
Capecitabine—Constipation—Mitoxantrone—lymphatic system cancer	3.44e-05	0.000501	CcSEcCtD
Capecitabine—Body temperature increased—Carmustine—lymphatic system cancer	3.42e-05	0.000499	CcSEcCtD
Capecitabine—Abdominal pain—Carmustine—lymphatic system cancer	3.42e-05	0.000499	CcSEcCtD
Capecitabine—Abdominal discomfort—Methotrexate—lymphatic system cancer	3.38e-05	0.000492	CcSEcCtD
Capecitabine—Gastrointestinal pain—Vincristine—lymphatic system cancer	3.38e-05	0.000492	CcSEcCtD
Capecitabine—Pancytopenia—Methotrexate—lymphatic system cancer	3.35e-05	0.000488	CcSEcCtD
Capecitabine—Feeling abnormal—Mitoxantrone—lymphatic system cancer	3.32e-05	0.000483	CcSEcCtD
Capecitabine—Neutropenia—Methotrexate—lymphatic system cancer	3.3e-05	0.00048	CcSEcCtD
Capecitabine—Dysuria—Methotrexate—lymphatic system cancer	3.3e-05	0.00048	CcSEcCtD
Capecitabine—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	3.29e-05	0.000479	CcSEcCtD
Capecitabine—Upper respiratory tract infection—Methotrexate—lymphatic system cancer	3.28e-05	0.000477	CcSEcCtD
Capecitabine—Abdominal pain—Vincristine—lymphatic system cancer	3.27e-05	0.000476	CcSEcCtD
Capecitabine—Body temperature increased—Vincristine—lymphatic system cancer	3.27e-05	0.000476	CcSEcCtD
Capecitabine—Photosensitivity reaction—Methotrexate—lymphatic system cancer	3.22e-05	0.000469	CcSEcCtD
Capecitabine—Urticaria—Mitoxantrone—lymphatic system cancer	3.2e-05	0.000466	CcSEcCtD
Capecitabine—Hypersensitivity—Carmustine—lymphatic system cancer	3.19e-05	0.000465	CcSEcCtD
Capecitabine—Abdominal pain—Mitoxantrone—lymphatic system cancer	3.18e-05	0.000464	CcSEcCtD
Capecitabine—Body temperature increased—Mitoxantrone—lymphatic system cancer	3.18e-05	0.000464	CcSEcCtD
Capecitabine—Pneumonia—Methotrexate—lymphatic system cancer	3.16e-05	0.000461	CcSEcCtD
Capecitabine—Vomiting—Bleomycin—lymphatic system cancer	3.15e-05	0.000459	CcSEcCtD
Capecitabine—Infestation NOS—Methotrexate—lymphatic system cancer	3.14e-05	0.000458	CcSEcCtD
Capecitabine—Infestation—Methotrexate—lymphatic system cancer	3.14e-05	0.000458	CcSEcCtD
Capecitabine—Depression—Methotrexate—lymphatic system cancer	3.13e-05	0.000457	CcSEcCtD
Capecitabine—Rash—Bleomycin—lymphatic system cancer	3.13e-05	0.000456	CcSEcCtD
Capecitabine—Dermatitis—Bleomycin—lymphatic system cancer	3.12e-05	0.000455	CcSEcCtD
Capecitabine—Stevens-Johnson syndrome—Methotrexate—lymphatic system cancer	3.12e-05	0.000454	CcSEcCtD
Capecitabine—Asthenia—Carmustine—lymphatic system cancer	3.11e-05	0.000453	CcSEcCtD
Capecitabine—Renal failure—Methotrexate—lymphatic system cancer	3.09e-05	0.00045	CcSEcCtD
Capecitabine—Stomatitis—Methotrexate—lymphatic system cancer	3.06e-05	0.000446	CcSEcCtD
Capecitabine—Conjunctivitis—Methotrexate—lymphatic system cancer	3.06e-05	0.000445	CcSEcCtD
Capecitabine—Hypersensitivity—Vincristine—lymphatic system cancer	3.04e-05	0.000444	CcSEcCtD
Capecitabine—Haematuria—Methotrexate—lymphatic system cancer	3e-05	0.000437	CcSEcCtD
Capecitabine—Hepatobiliary disease—Methotrexate—lymphatic system cancer	2.97e-05	0.000433	CcSEcCtD
Capecitabine—Epistaxis—Methotrexate—lymphatic system cancer	2.97e-05	0.000432	CcSEcCtD
Capecitabine—Hypersensitivity—Mitoxantrone—lymphatic system cancer	2.96e-05	0.000432	CcSEcCtD
Capecitabine—Asthenia—Vincristine—lymphatic system cancer	2.96e-05	0.000432	CcSEcCtD
Capecitabine—Diarrhoea—Carmustine—lymphatic system cancer	2.96e-05	0.000432	CcSEcCtD
Capecitabine—Nausea—Bleomycin—lymphatic system cancer	2.95e-05	0.000429	CcSEcCtD
Capecitabine—Agranulocytosis—Methotrexate—lymphatic system cancer	2.93e-05	0.000427	CcSEcCtD
Capecitabine—Asthenia—Mitoxantrone—lymphatic system cancer	2.89e-05	0.000421	CcSEcCtD
Capecitabine—Dizziness—Carmustine—lymphatic system cancer	2.86e-05	0.000417	CcSEcCtD
Capecitabine—Haemoglobin—Methotrexate—lymphatic system cancer	2.84e-05	0.000413	CcSEcCtD
Capecitabine—Diarrhoea—Vincristine—lymphatic system cancer	2.83e-05	0.000412	CcSEcCtD
Capecitabine—Haemorrhage—Methotrexate—lymphatic system cancer	2.82e-05	0.000411	CcSEcCtD
Capecitabine—Hepatitis—Methotrexate—lymphatic system cancer	2.82e-05	0.000411	CcSEcCtD
Capecitabine—Pharyngitis—Methotrexate—lymphatic system cancer	2.8e-05	0.000408	CcSEcCtD
Capecitabine—Urinary tract disorder—Methotrexate—lymphatic system cancer	2.79e-05	0.000406	CcSEcCtD
Capecitabine—Urethral disorder—Methotrexate—lymphatic system cancer	2.77e-05	0.000403	CcSEcCtD
Capecitabine—Diarrhoea—Mitoxantrone—lymphatic system cancer	2.75e-05	0.000401	CcSEcCtD
Capecitabine—Vomiting—Carmustine—lymphatic system cancer	2.75e-05	0.000401	CcSEcCtD
Capecitabine—Dizziness—Vincristine—lymphatic system cancer	2.73e-05	0.000398	CcSEcCtD
Capecitabine—Rash—Carmustine—lymphatic system cancer	2.73e-05	0.000398	CcSEcCtD
Capecitabine—Dermatitis—Carmustine—lymphatic system cancer	2.73e-05	0.000397	CcSEcCtD
Capecitabine—Visual impairment—Methotrexate—lymphatic system cancer	2.72e-05	0.000396	CcSEcCtD
Capecitabine—Headache—Carmustine—lymphatic system cancer	2.71e-05	0.000395	CcSEcCtD
Capecitabine—Erythema multiforme—Methotrexate—lymphatic system cancer	2.67e-05	0.000389	CcSEcCtD
Capecitabine—Eye disorder—Methotrexate—lymphatic system cancer	2.64e-05	0.000384	CcSEcCtD
Capecitabine—Tinnitus—Methotrexate—lymphatic system cancer	2.63e-05	0.000383	CcSEcCtD
Capecitabine—Vomiting—Vincristine—lymphatic system cancer	2.63e-05	0.000383	CcSEcCtD
Capecitabine—Cardiac disorder—Methotrexate—lymphatic system cancer	2.62e-05	0.000382	CcSEcCtD
Capecitabine—Rash—Vincristine—lymphatic system cancer	2.61e-05	0.00038	CcSEcCtD
Capecitabine—Dermatitis—Vincristine—lymphatic system cancer	2.6e-05	0.000379	CcSEcCtD
Capecitabine—Headache—Vincristine—lymphatic system cancer	2.59e-05	0.000377	CcSEcCtD
Capecitabine—Nausea—Carmustine—lymphatic system cancer	2.57e-05	0.000375	CcSEcCtD
Capecitabine—Angiopathy—Methotrexate—lymphatic system cancer	2.56e-05	0.000373	CcSEcCtD
Capecitabine—Vomiting—Mitoxantrone—lymphatic system cancer	2.56e-05	0.000373	CcSEcCtD
Capecitabine—Immune system disorder—Methotrexate—lymphatic system cancer	2.55e-05	0.000371	CcSEcCtD
Capecitabine—Mediastinal disorder—Methotrexate—lymphatic system cancer	2.54e-05	0.000371	CcSEcCtD
Capecitabine—Rash—Mitoxantrone—lymphatic system cancer	2.54e-05	0.00037	CcSEcCtD
Capecitabine—Dermatitis—Mitoxantrone—lymphatic system cancer	2.53e-05	0.000369	CcSEcCtD
Capecitabine—Chills—Methotrexate—lymphatic system cancer	2.53e-05	0.000369	CcSEcCtD
Capecitabine—Headache—Mitoxantrone—lymphatic system cancer	2.52e-05	0.000367	CcSEcCtD
Capecitabine—Alopecia—Methotrexate—lymphatic system cancer	2.49e-05	0.000363	CcSEcCtD
Capecitabine—Mental disorder—Methotrexate—lymphatic system cancer	2.47e-05	0.00036	CcSEcCtD
Capecitabine—Erythema—Methotrexate—lymphatic system cancer	2.46e-05	0.000358	CcSEcCtD
Capecitabine—Malnutrition—Methotrexate—lymphatic system cancer	2.46e-05	0.000358	CcSEcCtD
Capecitabine—Nausea—Vincristine—lymphatic system cancer	2.45e-05	0.000358	CcSEcCtD
Capecitabine—Dysgeusia—Methotrexate—lymphatic system cancer	2.41e-05	0.000351	CcSEcCtD
Capecitabine—Nausea—Mitoxantrone—lymphatic system cancer	2.39e-05	0.000348	CcSEcCtD
Capecitabine—Back pain—Methotrexate—lymphatic system cancer	2.38e-05	0.000346	CcSEcCtD
Capecitabine—Vision blurred—Methotrexate—lymphatic system cancer	2.32e-05	0.000337	CcSEcCtD
Capecitabine—Ill-defined disorder—Methotrexate—lymphatic system cancer	2.28e-05	0.000332	CcSEcCtD
Capecitabine—Anaemia—Methotrexate—lymphatic system cancer	2.27e-05	0.000331	CcSEcCtD
Capecitabine—Malaise—Methotrexate—lymphatic system cancer	2.22e-05	0.000323	CcSEcCtD
Capecitabine—Vertigo—Methotrexate—lymphatic system cancer	2.21e-05	0.000322	CcSEcCtD
Capecitabine—Leukopenia—Methotrexate—lymphatic system cancer	2.2e-05	0.00032	CcSEcCtD
Capecitabine—Cough—Methotrexate—lymphatic system cancer	2.14e-05	0.000312	CcSEcCtD
Capecitabine—Myalgia—Methotrexate—lymphatic system cancer	2.09e-05	0.000305	CcSEcCtD
Capecitabine—Chest pain—Methotrexate—lymphatic system cancer	2.09e-05	0.000305	CcSEcCtD
Capecitabine—Arthralgia—Methotrexate—lymphatic system cancer	2.09e-05	0.000305	CcSEcCtD
Capecitabine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	2.08e-05	0.000303	CcSEcCtD
Capecitabine—Discomfort—Methotrexate—lymphatic system cancer	2.07e-05	0.000301	CcSEcCtD
Capecitabine—Confusional state—Methotrexate—lymphatic system cancer	2.02e-05	0.000295	CcSEcCtD
Capecitabine—Infection—Methotrexate—lymphatic system cancer	1.99e-05	0.00029	CcSEcCtD
Capecitabine—Nervous system disorder—Methotrexate—lymphatic system cancer	1.97e-05	0.000286	CcSEcCtD
Capecitabine—Thrombocytopenia—Methotrexate—lymphatic system cancer	1.96e-05	0.000286	CcSEcCtD
Capecitabine—Skin disorder—Methotrexate—lymphatic system cancer	1.95e-05	0.000284	CcSEcCtD
Capecitabine—Hyperhidrosis—Methotrexate—lymphatic system cancer	1.94e-05	0.000282	CcSEcCtD
Capecitabine—Anorexia—Methotrexate—lymphatic system cancer	1.91e-05	0.000278	CcSEcCtD
Capecitabine—Hypotension—Methotrexate—lymphatic system cancer	1.87e-05	0.000273	CcSEcCtD
Capecitabine—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	1.83e-05	0.000266	CcSEcCtD
Capecitabine—Insomnia—Methotrexate—lymphatic system cancer	1.81e-05	0.000264	CcSEcCtD
Capecitabine—Paraesthesia—Methotrexate—lymphatic system cancer	1.8e-05	0.000262	CcSEcCtD
Capecitabine—Dyspnoea—Methotrexate—lymphatic system cancer	1.79e-05	0.00026	CcSEcCtD
Capecitabine—Dyspepsia—Methotrexate—lymphatic system cancer	1.76e-05	0.000257	CcSEcCtD
Capecitabine—Decreased appetite—Methotrexate—lymphatic system cancer	1.74e-05	0.000254	CcSEcCtD
Capecitabine—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	1.73e-05	0.000252	CcSEcCtD
Capecitabine—Fatigue—Methotrexate—lymphatic system cancer	1.73e-05	0.000252	CcSEcCtD
Capecitabine—Pain—Methotrexate—lymphatic system cancer	1.71e-05	0.00025	CcSEcCtD
Capecitabine—Feeling abnormal—Methotrexate—lymphatic system cancer	1.65e-05	0.000241	CcSEcCtD
Capecitabine—Gastrointestinal pain—Methotrexate—lymphatic system cancer	1.64e-05	0.000239	CcSEcCtD
Capecitabine—Urticaria—Methotrexate—lymphatic system cancer	1.59e-05	0.000232	CcSEcCtD
Capecitabine—Abdominal pain—Methotrexate—lymphatic system cancer	1.58e-05	0.000231	CcSEcCtD
Capecitabine—Body temperature increased—Methotrexate—lymphatic system cancer	1.58e-05	0.000231	CcSEcCtD
Capecitabine—Hypersensitivity—Methotrexate—lymphatic system cancer	1.48e-05	0.000215	CcSEcCtD
Capecitabine—Asthenia—Methotrexate—lymphatic system cancer	1.44e-05	0.00021	CcSEcCtD
Capecitabine—Pruritus—Methotrexate—lymphatic system cancer	1.42e-05	0.000207	CcSEcCtD
Capecitabine—Diarrhoea—Methotrexate—lymphatic system cancer	1.37e-05	0.0002	CcSEcCtD
Capecitabine—Dizziness—Methotrexate—lymphatic system cancer	1.33e-05	0.000193	CcSEcCtD
Capecitabine—Vomiting—Methotrexate—lymphatic system cancer	1.27e-05	0.000186	CcSEcCtD
Capecitabine—Rash—Methotrexate—lymphatic system cancer	1.26e-05	0.000184	CcSEcCtD
Capecitabine—Dermatitis—Methotrexate—lymphatic system cancer	1.26e-05	0.000184	CcSEcCtD
Capecitabine—Headache—Methotrexate—lymphatic system cancer	1.26e-05	0.000183	CcSEcCtD
Capecitabine—Nausea—Methotrexate—lymphatic system cancer	1.19e-05	0.000174	CcSEcCtD
